(GJAN) First Trust Exchange-Traded - Ratings and Ratios
Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US33740F5162 • Defined Outcome
GJAN: Options, Stocks
The First Trust Exchange-Traded Fund VIII - FT Cboe Vest U.S. Equity Moderate Buffer ETF - January (GJAN) is designed to provide investors with exposure to the S&P 500® Index while incorporating a buffer against potential losses. Under normal market conditions, the fund allocates substantially all of its assets to Flex Options, which are based on the SPDR® S&P 500® ETF Trust (SPY). These options are structured to offer a defined outcome, aiming to limit downside risk while allowing participation in potential upside. The fund is classified as non-diversified, meaning it can concentrate its investments, which may increase risk but also potentially enhance returns.
The underlying SPDR® S&P 500® ETF Trust (SPY) is a unit investment trust that employs a replication strategy, seeking to track the performance of the S&P 500® Index by holding as many of the indexs constituent stocks as practicable. This approach ensures that the ETF closely mirrors the indexs performance, providing broad exposure to the U.S. large-cap equity market. The funds use of SPY as the reference asset allows it to leverage the liquidity and stability of one of the most widely traded ETFs in the market.
As a defined outcome ETF, GJAN is tailored for investors seeking risk management within their equity portfolios. The funds strategy is designed to appeal to those who want to participate in the growth of the S&P 500® Index but are also looking to mitigate potential losses during market downturns. This makes it particularly suitable for risk-averse investors or those seeking to balance their portfolios with a buffered equity exposure.
3-Month Forecast: Based on the technical and fundamental data, GJAN is expected to maintain its stable performance. The funds short-term moving averages (SMA 20 and SMA 50) are slightly above its longer-term SMA 200, indicating a bullish trend. The Average True Range (ATR) of 0.27 suggests low volatility, which aligns with the funds risk-mitigating strategy. With an AUM of $381.64M, the fund has sufficient liquidity to support investor activity. Over the next three months, GJAN is likely to continue tracking the S&P 500® Index with a moderate buffer, providing investors with a balanced risk-return profile.
Additional Sources for GJAN ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
GJAN ETF Overview
Market Cap in USD | 377m |
Category | Defined Outcome |
TER | 0.85% |
IPO / Inception | 2023-01-20 |
GJAN ETF Ratings
Growth 5y | 59.2% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -3.23 |
Analysts | - |
Fair Price Momentum | 35.84 USD |
Fair Price DCF | - |
GJAN Dividends
No Dividends PaidGJAN Growth Ratios
Growth Correlation 3m | 8.9% |
Growth Correlation 12m | 95% |
Growth Correlation 5y | 98.4% |
CAGR 5y | 10.01% |
CAGR/Max DD 5y | 1.87 |
Sharpe Ratio 12m | 1.64 |
Alpha | -0.70 |
Beta | 0.31 |
Volatility | 13.92% |
Current Volume | 39.9k |
Average Volume 20d | 43.1k |
As of March 14, 2025, the stock is trading at USD 37.28 with a total of 39,900 shares traded.
Over the past week, the price has changed by -2.20%, over one month by -5.09%, over three months by -3.42% and over the past year by +4.75%.
Partly, yes. Based on ValueRay Analyses, First Trust Exchange-Traded (BATS:GJAN) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 59.24 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GJAN as of March 2025 is 35.84. This means that GJAN is currently overvalued and has a potential downside of -3.86%.
First Trust Exchange-Traded has no consensus analysts rating.
According to ValueRays Forecast Model, GJAN First Trust Exchange-Traded will be worth about 38.9 in March 2026. The stock is currently trading at 37.28. This means that the stock has a potential upside of +4.45%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 38.9 | 4.5% |